1000296-70-7
1000296-70-7
Chemical Structure
Sulopenem etzadroxil
Synonym(s): PF-03709270
- CAS No.: 1000296-70-7
- Formula:C19H27NO7S3
- Molecular Weight:477.62
IUPAC Name: ((2-ethylbutanoyl)oxy)methyl (5R,6S)-6-((R)-1-hydroxyethyl)-3-(((1R,3S)-1-oxidotetrahydrothiophen-3-yl)thio)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
InChIKey: NBPVNGWRLGHULH-CSOWVJSESA-N
SMILES: O=C(C(N12)=C(S[C@@H](CC3)C[S@@]3=O)S[C@]2([H])[C@@H]([C@H](O)C)C1=O)OCOC(C(CC)CC)=O
Biological Activity: Sulopenem etzadroxil is an orally active prodrug of the antibiotic Sulopenem (HY-105284). Sulopenem etzadroxil is active in mice infected with Bacillus anthracis[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sulopenem etzadroxil | 99.82% | Sulopenem etzadroxil is an orally active prodrug of the antibiotic Sulopenem (HY-105284). Sulopenem etzadroxil is active in mice infected with Bacillus anthracis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sulopenem etzadroxil (Standard) | ≥98% | Sulopenem etzadroxil (Standard) is the analytical standard of Sulopenem etzadroxil (HY-109754). This product is intended for research and analytical applications. Sulopenem etzadroxil is an orally active prodrug of the antibiotic Sulopenem (HY-105284). Sulopenem etzadroxil is active in mice infected with Bacillus anthracis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Bush K, et al. New β-lactam antibiotics and β-lactamase inhibitors. Expert opinion on therapeutic patents, 2010, 20(10): 1277-1293.
- [2]. Puttagunta S, et al. 1724. Murine Efficacy Studies of Sulopenem Against Bacillus anthracis[C]//Open Forum Infectious Diseases. US: Oxford University Press, 2022, 9(Supplement_2): ofac492. 1354.
- [3]. Zhanel GG, et al. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria. Drugs. 2022 Apr;82(5):533-557. [Content Brief]
